Ralph Dr. Kern - 06 Mar 2022 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: COO and Chief Medical Officer
Issuer ticker: BCLI
Reported as of: 06 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Mar 2022, 20:00:52 UTC
Prior SEC filing: 10 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Ralph Kern

Key filing fact

Ralph Dr. Kern filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 14 Mar 2022.

Key facts

This page summarizes Ralph Dr. Kern's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Mar 2022, 20:00.

Change

Previous filing in this sequence was filed on 10 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value: $0
Shares: +35,885
Change %: +19%
Price: $0.000000
Shares after: 223,310
Date: 06 Mar 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.